Course Summary
Contact Hour(s):
2 Contact Hours, including 2 Pharmacology Hours
Author:
Krystle Maynard, DNP, RN, SANE-A
This peer-reviewed course is applicable for the following professions:
Advanced Practice Registered Nurse (APRN), Certified Nurse Midwife, Certified Nurse Practitioner, Certified Registered Nurse Anesthetist (CRNA), Certified Registered Nurse Practitioner, Clinical Nurse Specialist (CNS), Licensed Practical Nurse (LPN), Licensed Vocational Nurses (LVN), Midwife (MW), Nursing Student, Registered Nurse (RN), Registered Nurse Practitioner
Accreditations:
The American Nurses Credentialing Center (ANCC)
State Approvals:
Alabama, Provider #ABNP1485; California BRN Provider #CEP # 13509; Kentucky Board of Nursing Provider #7-0085; Florida Board of Nursing Provider 50-353
Course Description:
This course discusses the challenges of managing acute and chronic pain while maintaining safe prescribing practices. Content includes the risks of misuse, abuse, and addiction associated with controlled substances, information on pain assessment, and an overview of Tennessee regulations related to controlled-substance prescribing.
Outcomes:
≥ 92% of participants will know how to incorporate both pharmacologic and non-pharmacologic therapies into a comprehensive, patient-centered plan for chronic pain.
Objectives:
After completing this continuing education course, the participant will be able to:
- Identify the risks of misuse, abuse, and addiction associated with controlled substances.
- Describe the key elements of a comprehensive pain assessment and methods to evaluate therapeutic outcomes.
- Apply evidence-based principles and Tennessee regulatory requirements for the safe and effective prescribing of controlled substances.
- Specify appropriate risk-mitigation strategies to promote patient safety.
- Compare pharmacologic and non-pharmacologic pain management modalities to support individualized, patient-centered care.
Disclosures:
CEUFast Inc. and the course planning team for this educational activity do not have any relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
